Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biospecifics Tech Cp (BSTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 485,740
  • Shares Outstanding, K 7,278
  • Annual Sales, $ 27,440 K
  • Annual Income, $ 11,330 K
  • 60-Month Beta 1.29
  • Price/Sales 16.38
  • Price/Cash Flow 33.97
  • Price/Book 5.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.68
  • Number of Estimates 1
  • High Estimate 0.68
  • Low Estimate 0.68
  • Prior Year 0.51
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.15 +2.36%
on 03/19/19
72.83 -8.43%
on 03/04/19
-4.81 (-6.73%)
since 02/19/19
3-Month
52.71 +26.52%
on 12/24/18
73.31 -9.03%
on 02/19/19
+3.89 (+6.19%)
since 12/19/18
52-Week
40.54 +64.50%
on 04/30/18
73.31 -9.03%
on 02/19/19
+23.98 (+56.15%)
since 03/19/18

Most Recent Stories

More News
BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed...

BSTC : 66.69 (-0.07%)
What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.

ENDP : 8.77 (+2.10%)
BDSI : 4.94 (+0.61%)
TLRY : 69.79 (-3.39%)
BSTC : 66.69 (-0.07%)
Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN),...

ABUS : 3.73 (-3.37%)
AMRN : 18.86 (-2.28%)
RUN : 14.68 (-1.01%)
RTRX : 24.23 (+1.13%)
TOCA : 10.74 (-0.56%)
BSTC : 66.69 (-0.07%)
BioSpecifics (BSTC) Upgraded to Buy: Here's What You Should Know

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BSTC : 66.69 (-0.07%)
Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?

Is (BSTC) Outperforming Other Medical Stocks This Year?

BSTC : 66.69 (-0.07%)
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza

Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.

CPIX : 5.90 (-1.38%)
HKMPF : 21.1000 (-4.52%)
BSTC : 66.69 (-0.07%)
OCUL : 4.10 (+0.99%)
INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening...

MYL : 28.62 (+1.56%)
INSY : 4.81 (+9.57%)
TEVA : 16.91 (+1.62%)
BSTC : 66.69 (-0.07%)
Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?

Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

BSTC : 66.69 (-0.07%)
CSBR : 11.14 (+5.00%)
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU

Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.

JNJ : 138.44 (+0.93%)
HKMPF : 21.1000 (-4.52%)
KPTI : 5.35 (+0.75%)
BSTC : 66.69 (-0.07%)
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

NBIX : 87.62 (+3.31%)
HKMPF : 21.1000 (-4.52%)
ABBV : 80.82 (+0.21%)
BSTC : 66.69 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade BSTC with:

Business Summary

BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (``FDA``) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for...

See More

Key Turning Points

2nd Resistance Point 69.31
1st Resistance Point 68.00
Last Price 66.69
1st Support Level 65.27
2nd Support Level 63.84

See More

52-Week High 73.31
Last Price 66.69
Fibonacci 61.8% 60.79
Fibonacci 50% 56.92
Fibonacci 38.2% 53.06
52-Week Low 40.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar